Korean J Med.  2011 Jun;80(Suppl 2):S273-S277.

Rituximab Plus CHOP for the Treatment of Primary Mediastinal Large B Cell Lymphoma in a Pregnant Woman

• Kim EK
• Kim SJ
• Park SB
• Cho JH
• Ko YH
• Kim WS

Abstract

A 33-year-old woman developed primary mediastinal large B-cell lymphoma (PMLBCL) during the second trimester of pregnancy. She was immediately treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP). After the third cycle of R-CHOP, she delivered a healthy baby by Caesarian section. She was in complete response after she finished all courses of treatment, and the rituximab-containing chemotherapy during pregnancy induced no adverse effect in the fetus. Thus, R-CHOP appears to be an effective, safe treatment option for PMLBCL encountered during the second and third trimesters of pregnancy. To our knowledge, this is the first report of the use of rituximab plus CHOP in a pregnant woman in Korea.

Keyword

Lymphoma, Non-Hodgkin; Therapy; Pregnancy; Rituximab

MeSH Terms

Adult
Antibodies, Monoclonal, Murine-Derived
Cyclophosphamide
Doxorubicin
Female
Fetus
Humans
Korea
Lymphoma, B-Cell
Lymphoma, Non-Hodgkin
Prednisolone
Pregnancy
Pregnancy Trimester, Second
Pregnancy Trimester, Third
Pregnant Women
Vincristine
Rituximab
Antibodies, Monoclonal, Murine-Derived
Cyclophosphamide
Doxorubicin
Prednisolone
Vincristine